Skip to main content
. Author manuscript; available in PMC: 2019 Jan 2.
Published in final edited form as: Nat Rev Drug Discov. 2016 Dec 2;16(1):19–34. doi: 10.1038/nrd.2016.230

Figure 6.

Figure 6

Overlap of cancer drug targets with cancer drivers. We grouped the cancer drugs into the three categories: broadly cytotoxic agents such as platinum complexes and DNA intercalating agents; cytotoxic agents that act through a protein, such as tubulin inhibitors, that do not have biological selectivity; and targeted agents that act through clear protein function-modulating mechanisms such as kinase inhibitors and nuclear hormone receptor antagonists. When we compared the targets of agents in the third group to a consensus reference list on cancer driver genes43 we observe only a small overlap between cancer drivers and current cancer drug targets.